about
Drug interactions and immunosuppression in organ transplant recipientsFluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation.Each administration of cyclosporin A enhances skin microvascular reactivity in renal transplant recipients.Association between insulin resistance and endothelial dysfunction in renal transplant recipients.Calcineurin inhibitor effects on glucose metabolism and endothelial function following renal transplantation.Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modellingFluvastatin and fluvastatin extended release: a clinical and safety profile.Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients.A drug safety evaluation of everolimus in kidney transplantation.The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.Collectin Liver 1 and Collectin Kidney 1 of the Lectin Complement Pathway Are Associated With Mortality After Kidney Transplantation.Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.Rimonabant affects cyclosporine a, but not tacrolimus pharmacokinetics in renal transplant recipients.Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance.Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'.Treatment of Cytomegalovirus Disease in Solid Organ Transplant RecipientsAccelerated 18O-labeling in urinary proteomicsSmall effort, high impact: Focus on physical activity improves oxygen uptake (VO2peak ), quality of life, and mental health after pediatric renal transplantationWhy dose adjust systemic exposure when looking for associations with adverse events in tacrolimus-treated transplant recipients?
P50
Q27013722-5E8F1848-2368-45A3-BA64-9F1D9EAF98D4Q30729591-D515CC56-BBDA-4D6A-8495-DCC80AAEA029Q30912779-9C826E13-DE25-4DA7-BBB6-59EB77BB0BFEQ33241175-2968623F-F5EC-4F0D-BB72-E683DBA37D82Q33408297-92BF0F1C-0396-4201-9683-DD2C0D6B4DF4Q34571036-ADE766EB-E593-49EA-83E7-999B21FAE41DQ35879055-4AA02999-5804-4E90-A4B2-E799297894F9Q37724248-0CF07A11-CA7E-42AD-9C71-631A3B2E9450Q38041260-6C1E3443-9054-4B1F-AD15-3ECB0D326833Q38986439-145C569C-2C3C-4A5E-956D-A5C2ABA6A4DFQ39657040-3C1D87B1-2E49-4143-8E97-CA09E7EC9786Q43533863-D555F24C-1131-4509-8DAD-F62B1052F63AQ46041720-A5131640-9560-496A-83E6-5D10B3A254A8Q48122426-565189C4-9CF1-4EB5-9521-396D1A776100Q48325082-64131B96-3BAD-4192-981A-A9167B709B9CQ57750433-58B1DE64-BF88-47E6-8330-879BB1785CBBQ82539095-1783893D-A216-4D29-87EF-48AF5FA35A9CQ89155623-0BD9DF19-8145-4EAF-A44A-C32FF0134E0EQ92390902-25A6CEC9-4FDB-46F5-BBE5-7275839CDB5A
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Anders Åsberg
@ast
Anders Åsberg
@en
Anders Åsberg
@es
Anders Åsberg
@nl
Anders Åsberg
@sl
type
label
Anders Åsberg
@ast
Anders Åsberg
@en
Anders Åsberg
@es
Anders Åsberg
@nl
Anders Åsberg
@sl
prefLabel
Anders Åsberg
@ast
Anders Åsberg
@en
Anders Åsberg
@es
Anders Åsberg
@nl
Anders Åsberg
@sl
P106
P31
P496
0000-0002-0628-1769